Skip to content

Pancreaticoduodenectomy with Portal Vein-Superior Mesenteric Vein Resection and Reconstruction for Periampullary Carcinoma: A Prospective Cohort Study Comparing Robotic Surgery with Open Surgery

Pancreaticoduodenectomy with Portal Vein-Superior Mesenteric Vein Resection and Reconstruction for Periampullary Carcinoma: A Prospective Cohort Study Comparing Robotic Surgery with Open Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124506
Enrollment
Unknown
Registered
2026-05-13
Start date
2026-05-18
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periampullary Carcinoma:

Interventions

Observation group:None
Control group:None

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age between 18 and 85 years 2.ECOG performance status score of 0–1 3.Radiologically confirmed periampullary carcinoma with portal vein-superior mesenteric vein (PV-SMV) invasion but no superior mesenteric artery (SMA) involvement 4.Restored portal venous flow feasible via vascular reconstruction (end-to-end anastomosis, artificial or autologous vascular graft) 5.Voluntarily signed informed consent 6.Discontinuation of preoperative systemic therapy for =4 weeks (=6 weeks for immunotherapy) with no disease progression confirmed radiologically

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation 2.Preoperative evaluation showing arterial invasion (e.g., extensive involvement of the superior mesenteric artery or hepatic artery) or distant metastasis, rendering radical resection impossible 3.Severe cardiac, pulmonary, hepatic or renal dysfunction precluding tolerance to surgery and anesthesia 4.Unresectable distant metastasis or second primary malignancy 5.Uncontrolled biliary tract infection or sepsis within 7 days preoperatively 6.Intraoperative findings of extensive peritoneal metastasis or multifocal liver dissemination precluding R0 resection

Design outcomes

Primary

MeasureTime frame
Overall incidence of complications within 30 days postoperatively;

Secondary

MeasureTime frame
Specific postoperative complications included pancreatic fistula, biliary fistula, gastrointestinal anastomotic leakage, intra-abdominal infection, and abdominal cavity Bleeding, pulmonary infection, incision infection, etc;All-cause mortality rates at 30 days and 90 days after the surgery;Intraoperative indicators: operation time, intraoperative blood loss, intraoperative blood transfusion rate;Postoperative recovery indicators included first exhaust time, first feeding time, postoperative hospital stay, ICU admission rate and length of stay.;Oncology indicators included R0 resection rate, number of lymph node dissection and number of positive lymph nodes;Long-term prognosis: disease-free survival (DFS), overall survival (OS);Total cost of hospitalization;

Countries

China

Contacts

Public ContactZhang Wen

The First Affiliated Hospital of Guangxi Medical University

lantsgxmu@163.com+86 138 7810 8107

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026